Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Bachem Holding AG
  6. News
  7. Summary
    BANB   CH0012530207

BACHEM HOLDING AG

(BANB)
  Report
Delayed Quote. Delayed Swiss Exchange - 08/05 11:30:28 am
609 CHF   -1.46%
07/23BACHEM : The weight loss drug Liraglutide
PU
07/20BACHEM : What are oligonucleotides?
PU
07/20BACHEM : Interview with Amy Zhang, Head of Supply Chain at Luye Pharma
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Bachem : A world market leader from the Basel region – Bachem celebrates 50 years of company history

06/15/2021 | 05:18am EDT

Bachem (SIX: BANB) celebrates its fifty-year anniversary tomorrow Thursday, 16 June 2021.

Bachem was founded in 1971 by the entrepreneur Peter Grogg. Over the course of half a century Bachem has become a global leader in the development and production of peptides, important ingredients for a range of vital medicines that treat cancer, diabetes and other diseases.

Today we celebrate 50 exciting and successful years of company history. Bachem's success continues to be rooted in the skills and dedication of its employees. I am certain that Bachem has many more exciting and successful years ahead of it.

Peter Grogg

Company Founder

In 1977, Bachem moved with eight employees to Bubendorf, where the company remains headquartered today. Its portfolio makes Bachem an important supplier to the global pharmaceutical and biotechnology industry.

Bachem's exceptional success story from a small laboratory to a global market leader is closely linked to Peter Grogg's values and has been shaped by innovation, consistent quality and cost awareness, as well as by entrepreneurial vision.

Kuno Sommer

Chairman of the Board of Directors

What started out as a small laboratory has grown into a company that employs over 1,500 people at six locations worldwide. Last year, despite pandemic conditions, Bachem generated over CHF 400 million for the first time and hired 272 new employees. Bachem intends to grow further in the coming years and plans to invest more than CHF 400 million in the expansion of the company over the next five years.

The anniversary celebrations for employees, originally planned on site, will be held as a virtual event due to the COVID-19 pandemic.

Today's anniversary is a commitment to the next 50 years. We intend and are able to continue to grow independently and profitably. That is why we are continuing to invest in the future of all our sites. In doing so, we will build on our strengths: our company culture and our commitment to high quality, innovation and customer focus.

Thomas Meier

CEO

Downloads

About Bachem
Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. The company, which has 50 years of experience and expertise, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services. Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange. For further information, see www.bachem.com.

Bachem celebrates fifty years of company history. From Peter Grogg's business idea in the 1970s to the world's leading company in the development and production of peptides and oligonucleotides. A success story based on courage, innovation, quality, partnership, and unique people.

50 Years Bachem

For more information:

Bachem Holding AG
Dr. Daniel Grotzky
Head Group Communications
Tel.: +41 58 595 2021

Media:media@bachem.com
Investors:ir@bachem.com

Contact US
  • Name*
    First NameLast Name
  • Job Title
  • Company Name
  • Business unit/Dept.
  • Email Address*
  • Address*
    Street AddressCityStateZIP / Postal CodeCountryAfghanistanAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaAntarcticaAntigua and BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBonaire, Sint Eustatius and SabaBosnia and HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBrunei DarussalamBulgariaBurkina FasoBurundiCambodiaCameroonCanadaCape VerdeCayman IslandsCentral African RepublicChadChileChinaChristmas IslandCocos IslandsColombiaComorosCongo, Democratic Republic of theCongo, Republic of theCook IslandsCosta RicaCroatiaCubaCuraçaoCyprusCzech RepublicCôte d'IvoireDenmarkDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEswatini (Swaziland)EthiopiaFalkland IslandsFaroe IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuamGuatemalaGuernseyGuineaGuinea-BissauGuyanaHaitiHeard and McDonald IslandsHoly SeeHondurasHong KongHungaryIcelandIndiaIndonesiaIranIraqIrelandIsle of ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiKuwaitKyrgyzstanLao People's Democratic RepublicLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacauMacedoniaMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMartiniqueMauritaniaMauritiusMayotteMexicoMicronesiaMoldovaMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorth KoreaNorthern Mariana IslandsNorwayOmanPakistanPalauPalestine, State ofPanamaPapua New GuineaParaguayPeruPhilippinesPitcairnPolandPortugalPuerto RicoQatarRomaniaRussiaRwandaRéunionSaint BarthélemySaint HelenaSaint Kitts and NevisSaint LuciaSaint MartinSaint Pierre and MiquelonSaint Vincent and the GrenadinesSamoaSan MarinoSao Tome and PrincipeSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSint MaartenSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth GeorgiaSouth KoreaSouth SudanSpainSri LankaSudanSurinameSvalbard and Jan Mayen IslandsSwedenSwitzerlandSyriaTaiwanTajikistanTanzaniaThailandTimor-LesteTogoTokelauTongaTrinidad and TobagoTunisiaTurkeyTurkmenistanTurks and Caicos IslandsTuvaluUS Minor Outlying IslandsUgandaUkraineUnited Arab EmiratesUnited KingdomUnited StatesUruguayUzbekistanVanuatuVenezuelaVietnamVirgin Islands, BritishVirgin Islands, U.S.Wallis and FutunaWestern SaharaYemenZambiaZimbabweÅland Islands
  • Phone / Mobile
  • What can we help you with?
    Please selectOrder an annual reportAsk a question / request information
  • Comments
  • Please choose if you would like to receive additional email communications from Bachem:

  • Sign up for newsletter
    • Sign up for newsletter
  • Fields marked with an asterisk (*) are required

  • Hidden
    Refer Url.
  • Hidden
    Submission Time
    :Hours
    Minutes
  • Email
    This field is for validation purposes and should be left unchanged.

Disclaimer

Bachem Holding AG published this content on 15 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 June 2021 09:17:03 UTC.


ę Publicnow 2021
All news about BACHEM HOLDING AG
07/23BACHEM : The weight loss drug Liraglutide
PU
07/20BACHEM : What are oligonucleotides?
PU
07/20BACHEM : Interview with Amy Zhang, Head of Supply Chain at Luye Pharma
PU
07/12BACHEM : Somatostatin Analogues Provide Invaluable Therapeutic Options
PU
07/01BACHEM : What are somatostatin and somatostatin analogues?
PU
06/28BACHEM : innovating through virtual events
PU
06/23BACHEM : Introduction to Cell-Permeable Peptides
PU
06/22MEET BACHEM : Pascal Hess, Group Leader Generics & Portfolio
PU
06/22PRESS RELEASE : Santhera's Shareholders Approve all Board Proposals at Today's A..
DJ
06/17BACHEM : Mirabaud Securities Lifts Price Target on Bachem, Maintains Buy Recomme..
MT
More news
Financials
Sales 2021 486 M 535 M 535 M
Net income 2021 103 M 114 M 114 M
Net Debt 2021 151 M 166 M 166 M
P/E ratio 2021 82,6x
Yield 2021 0,57%
Capitalization 8 524 M 9 402 M 9 385 M
EV / Sales 2021 17,9x
EV / Sales 2022 15,0x
Nbr of Employees 1 475
Free-Float 42,9%
Chart BACHEM HOLDING AG
Duration : Period :
Bachem Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BACHEM HOLDING AG
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 609,00 CHF
Average target price 558,67 CHF
Spread / Average Target -8,26%
EPS Revisions
Managers and Directors
Thomas Meier Chief Executive Officer
Alain Schaffter Chief Financial Officer
Kuno Sommer Chairman
GŘnther Loidl Chief Technology Officer
Ralph Sch÷nleber Vice President-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
BACHEM HOLDING AG53.98%9 402
MODERNA, INC.301.12%168 260
LONZA GROUP AG26.76%59 023
IQVIA HOLDINGS INC.38.64%47 876
CELLTRION, INC.-25.07%32 166
SEAGEN INC.-7.39%29 694